J. Maraganore

发表

Interfering with disease: a progress report on siRNA-based therapeutics

Judy Lieberman, John Maraganore, J. Lieberman, 2007, Nature Reviews Drug Discovery.

Combination of Inhibition of Thrombin and Blockade of Thromboxane A2 Synthetase and Receptors Enhances Thrombolysis and Delays Reocclusion in Canine Coronary Arteries

H. Anderson, J. Willerson, J. Maraganore, 1992, Circulation.

US immigration order strikes against biotech

Christopher R. Westphal, Mara G. Aspinall, J. A. Scarlett, 2017, Nature Biotechnology.

The Effect of Thrombin Inhibitors on Tissue Plasminogen Activator Induced Thrombolysis in a Rat Model

J. Hirsh, J. Maraganore, G. Wilson, 1992, Thrombosis and Haemostasis.

Anticoagulant Activity of Hirulog™, a Direct Thrombin Inhibitor, in Humans

J. Maraganore, J. Wagner, J. Eisner, 1993, Thrombosis and Haemostasis.

Secretion of Active Human Tissue Plasminogen Activator from the Filamentous Fungus Aspergillus Nidulans

K. Lewison, J. Maraganore, M. Favreau, 1987, Bio/Technology.

Thrombin structure and function: why thrombin is the primary target for antithrombotics.

J. Maraganore, F. Ofosu, J. Fenton, 1991, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators.

B. Chaitman, J. Brinker, J. Bittl, 1995, The New England journal of medicine.

Structure of the hirugen and hirulog 1 complexes of alpha-thrombin.

A. Tulinsky, E. Skrzypczak‐Jankun, J. Maraganore, 1991, Journal of molecular biology.

Thrombin functions as an inflammatory mediator through activation of its receptor

J. Maraganore, G. Cirino, C. Cicala, 1996, The Journal of experimental medicine.

Heparin resistance in acute coronary syndromes

C. Cannon, J. Hirsh, P. Théroux, 2007, Journal of Thrombosis and Thrombolysis.

Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease.

E. Braunwald, C. Cannon, J. Loscalzo, 1993, The American journal of cardiology.

Inhibition by hirulog-1 of generation of plasminogen activator inhibitor-1 from vascular smooth-muscle cells induced by thrombin.

J. Maraganore, J. Fenton, S. Ren, 1997, Journal of cardiovascular pharmacology.

The COOH-terminal domain of hirudin. An exosite-directed competitive inhibitor of the action of alpha-thrombin on fibrinogen.

J. Shafer, S. Olson, J. Maraganore, 1990, The Journal of biological chemistry.

Hirudin and Hirulog: Advances in antithrombotic therapy

J. Maraganore, 1994 .

Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators.

R. Collins, H. White, W. Hillis, 1997, Circulation.

A 113-amino acid fragment of CD4 produced in Escherichia coli blocks human immunodeficiency virus-induced cell fusion.

J. J. Rosa, R. Schooley, T. Curiel, 1989, The Journal of biological chemistry.

The lysine-49 phospholipase A2 from the venom of Agkistrodon piscivorus piscivorus. Relation of structure and function to other phospholipases A2.

R. Heinrikson, J. Maraganore, 1986, The Journal of biological chemistry.

Comparison of enzymatic and pharmacological activities of lysine-49 and aspartate-49 phospholipases A2 from Agkistrodon piscivorus piscivorus snake venom.

R. Heinrikson, J. Maraganore, P. Rosenberg, 1987, Biochemical pharmacology.

A new class of phospholipases A2 with lysine in place of aspartate 49. Functional consequences for calcium and substrate binding.

R. Heinrikson, J. Maraganore, W. Cho, 1984, The Journal of biological chemistry.

Hirulog-1 and -B2 thrombin specificity.

J. Maraganore, J. Fenton, P. Bourdon, 1992, The Biochemical journal.

Essential groups in synthetic agonist peptides for activation of the platelet thrombin receptor.

J. Maraganore, S. Stone, S. Kalkunte, 1992, Biochemistry.

Hirulog effect in rat endotoxin shock.

J. Maraganore, G. Cirino, C. Cicala, 1995, Life sciences.

The arterial thrombotic process and emerging drugs for its control.

J. Maraganore, 1993, Texas Heart Institute journal.

Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin.

S. Hanson, J. Maraganore, L. Harker, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Inhibition of the amplification reactions of blood coagulation by site-specific inhibitors of alpha-thrombin.

J. Hirsh, J. Maraganore, M. Blajchman, 1992, The Biochemical journal.

Thrombin inhibition enhances tissue-type plasminogen activator-induced thrombolysis and delays reocclusion.

J. Eidt, H. Anderson, J. Willerson, 1992, The American journal of physiology.

Inhibition of coagulation and thrombin-induced platelet activities by a synthetic dodecapeptide modeled on the carboxy-terminus of hirudin

J. Maraganore, J. Jakubowski, 1990 .

Inhibition of coagulation and thrombin-induced platelet activities by a synthetic dodecapeptide modeled on the carboxy-terminus of hirudin.

J. Maraganore, J. Jakubowski, 1990, Blood.

Pre-clinical and clinical studies on Hirulog: a potent and specific direct thrombin inhibitor.

J. Maraganore, 1993, Advances in experimental medicine and biology.

Hirulog: a direct thrombin inhibitor for management of acute coronary syndromes.

J. Maraganore, B. Adelman, 1996, Coronary artery disease.

Thrombin inhibition by hirudin: how hirudin inhibits thrombin.

J. Maraganore, F. Ofosu, J. Fenton, 1991, Haemostasis.

Reflections on Alnylam

J. Maraganore, 2022, Nature Biotechnology.

A status report on RNAi therapeutics

John Maraganore, J. Gollob, J. Maraganore, 2010, Silence.

Selective inhibition by a synthetic hirudin peptide of fibrin-dependent thrombosis in baboons.

S. Hanson, J. Maraganore, L. Harker, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Anticoagulant activity of synthetic hirudin peptides.

J. Maraganore, J. Jablonski, K. Ramachandran, 1989, The Journal of biological chemistry.

Effects on Thrombin Generation of Single Injections of Hirulog™ in Patients with Calf Vein Thrombosis

J. Hirsh, M. Gent, J. Maraganore, 1994, Thrombosis and Haemostasis.

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.

D. Massel, J. Hirsh, J. Maraganore, 1990, The Journal of clinical investigation.

Isolation of an active-site peptide of lipoprotein lipase from bovine milk and determination of its amino acid sequence.

M. N. Reddy, R. Heinrikson, J. Maraganore, 1986, The Journal of biological chemistry.

Use of A Direct Antithrombin, Hirulog, in Place of Heparin During Coronary Angioplast

E. Topol, P. Ganz, V. Kakkar, 1993, Circulation.

Hirulog peptides with scissile bond replacements resistant to thrombin cleavage.

J. Maraganore, C. Hammond, T. Kline, 1991, Biochemical and biophysical research communications.

HIRUDIN INTERACTIONS WITH THROMBIN

J. Maraganore, S. Stone, 1992 .

Purification and characterization of trichosanthin. Homology to the ricin A chain and implications as to mechanism of abortifacient activity.

J. Maraganore, M. C. Bailey, M. Joseph, 1987, The Journal of biological chemistry.

Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin.

J. Maraganore, J. Jablonski, K. Ramachandran, 1990, Biochemistry.

Affinity labeling of lysine-149 in the anion-binding exosite of human alpha-thrombin with an N alpha-(dinitrofluorobenzyl)hirudin C-terminal peptide.

J. Maraganore, J. Fenton, P. Bourdon, 1990, Biochemistry.

Thrombin inhibition by synthetic hirudin peptides.

J. Maraganore, J. Fenton, 1990, Advances in experimental medicine and biology.

Agkistrodon piscivorus piscivorus platelet aggregation inhibitor: a potent inhibitor of platelet activation.

J. Maraganore, L. Harker, B. Savage, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Structural and functional properties of a phospholipase A2 purified from an inflammatory exudate.

I. Reardon, R. Heinrikson, J. Maraganore, 1986, Biochemistry.

Thrombin-specific inhibition by and slow cleavage of hirulog-1.

J. Maraganore, J. Fenton, P. Bourdon, 1992, The Biochemical journal.

Structure‐function relationships of hirulog peptide interactions with thrombin

J. Maraganore, J. Jablonski, B. Chao, 1991, FEBS letters.

Randomized, Double-blind Comparison of Hirulog Versus Heparin in Patients Receiving Streptokinase and Aspirin for Acute Myocardial Infarction (HERO)

R. Collins, H. White, P. Aylward, 1997 .

Initial Experience With a Direct Antithrombin, Hirulog, in Unstable Angina Anticoagulant, Antithrombotic, and Clinical Effects

M. Juneau, J. Maraganore, R. Lidón, 1993, Circulation.

Kinetic mechanism for the interaction of Hirulog with thrombin.

J. Maraganore, S. Stone, S R Stone, 1994, Biochemistry.

Thrombin, Thrombin Inhibitors, and the Arterial Thrombotic Process

J. Maraganore, 1993, Thrombosis and Haemostasis.

Systemic Thrombin Inhibition by Hirulog Does Not Alter Medial Smooth Muscle Cell Proliferation and Inflammatory Activation after Vascular Injury in the Rabbit

P. Libby, J. Maraganore, R. Kranzhöfer, 1999, Cardiovascular Drugs and Therapy.

Relation between binding and the action of phospholipases A2 on Escherichia coli exposed to the bactericidal/permeability-increasing protein of neutrophils.

R. Heinrikson, J. Maraganore, P. Elsbach, 1987, Biochimica et biophysica acta.

Binding of the snake venom-derived proteins applaggin and echistatin to the arginine-glycine-aspartic acid recognition site(s) on platelet glycoprotein IIb.IIIa complex inhibits receptor function.

J. Maraganore, L. Harker, B. Savage, 1990, The Journal of biological chemistry.

From adaptive licensing to adaptive pathways: Delivering a flexible life‐span approach to bring new drugs to patients

W Goettsch, D Samaha, G. Rasi, 2015, Clinical pharmacology and therapeutics.

Which class of serine is involved in the lipase mechanism

R. Heinrikson, J. Maraganore, 1986 .

Effectiveness of hirulog in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits.

J. Maraganore, I. Sarembock, E. Powers, 1996, Journal of vascular research.

A rapid method for the purification of monomeric and/or dimeric phospholipases A2 in crotalid snake venoms.

J. Maraganore, W. Welches, D. Felsher, 1985, Toxicon : official journal of the International Society on Toxinology.

ReviewA status report on RNAi therapeutics

J. Gollob, J. Maraganore, C. Gamba-Vitalo, 2015 .

Reviewreport on RNAi therapeutics

J. Gollob, J. Maraganore, C. Gamba-Vitalo, 2010 .

Characterization of the structure and function of three phospholipases A2 from the venom of Agkistrodon halys pallas.

I. Reardon, R. Heinrikson, J. Maraganore, 1987, Toxicon : official journal of the International Society on Toxinology.

Phospholipases A2: Variations on a structural theme and their implications as to mechanism

R. Heinrikson, R. Poorman, J. Maraganore, 1987 .

Clinical Development of Bivalirudin

R. Harrington, J. Maraganore, 2002 .

Hirudin and hirudin-based peptides.

J. Maraganore, S. Stone, 1993, Methods in enzymology.

The house that George built

John Maraganore, J. Maraganore, 2009, Nature Biotechnology.

Structure of the hirulog 3-thrombin complex and nature of the S' subsites of substrates and inhibitors.

A. Tulinsky, J. Maraganore, J W Fenton, 1994, Biochemistry.

Thrombin functions as an inflammatory mediator through activation of its receptor

J. Maraganore, G. Cirino, C. Cicala, 1996, The Journal of experimental medicine.

(54) NOVEL INHIBITORS OF THROMBIN NEUE THROMBININHIBITOREN NOUVEAUX INHIBITEURS DE THROMBINE (84) Designated Contracting States: AT BE CH DE DK ES FR GB IT LI LU NL SE

J. Maraganore, J. Krstenansky, 2010 .

A Practical Guide to the General Application of PTC-Amino Acid Analysis

R. Heinrikson, J. Maraganore, R. Mora, 1987 .